Table 1.
General characteristics of patient cohort.
| WHO Classification | N | % | Sex (M/F) | Age, y (SE) | Mean IPSS |
|---|---|---|---|---|---|
| MDS | |||||
| Low grade | |||||
| RA/RCMD | 13 | 17.6 | 6/7 | 67 ± 21 | 0.65§ |
| RARS/RCMD-RS | 9 | 12.2 | 5/4 | 69 ± 8 | 0.72 |
| 5q- syndrome | 4 | 5.4 | 1/3 | 54 ± 22 | 0.25 |
| MDS-U | 4 | 5.4 | 3/1 | 70 ± 11 | 0.5§ |
| Advanced grade | |||||
| RAEB1/2 | 22 | 29.7 | 17/5 | 64 ± 13 | 1.89§ |
| MDS/MPN | |||||
| MDS/MPN-U | 4 | 5.4 | 3/1 | 79 ± 5 | 1.25§ |
| CMML1/2 | 3 | 4.1 | 3/0 | 76 ± 2 | 0.5 |
| AML | |||||
| Primary AML | 4 | 5.4 | 2/2 | 57 ± 22 | NA |
| Secondary AML* | 11 | 14.8 | 7/4 | 72 ± 7 | 2.5ψ |
NA, not applicable.
*
RAEB-T accounts for 3 of 8 secondary AML (WHO).
§
includes patients that cannot be analyzed for IPSS due to non-informative cytogenetics.
ψ
Only patients with secondary AML who fulfilled FAB criteria for RAEB-T were included in IPSS.